WTF With Race Oncology: Changing The Chemo Game – Stockhead
WTF With Race Oncology: Changing The Chemo Game – Stockhead
Race Oncology (ASX:RAC) CEO Dr Daniel Tillett joins Sarah Hughan at the Stockhead’s What The Facts?! video interview series to discuss side effects of traditional chemotherapy and the importance of protecting heart health as patients go through...
Shareholder Options Q&A
Shareholder Options Q&A
We thank all our shareholders for their strong interest in the Race Oncology Bonus Options and Piggyback Options Offer. We have been receiving many questions in relation to these options, so to help we...
International Cardiometabolic Expert To Join Race Oncology’s Scientific Advisory Board
International Cardiometabolic Expert To Join Race Oncology’s Scientific Advisory Board
Special Report: Race oncology is further bolstering the expertise of its scientific advisory board with the appointment of an international cardiometabolic expert who has researched the effects of chemotherapy on cardiovascular fitness of cancer patients....
Race Oncology Looks To Accelerate Clinical Development Of Bisantrene
Race Oncology Looks To Accelerate Clinical Development Of Bisantrene
Race Oncology Ltd (ASX:RAC, OTC:RAONF) CEO Daniel Tillett joins Jonathan Jackson in the Proactive studio to provide an update on the company’s movements over the last few months. Just recently, Race received a $4 million R&D tax...
‘Significant Potential’: This ASX Stock Is Winning The Race To Make Cancer Care Heart-Safe
‘Significant Potential’: This ASX Stock Is Winning The Race To Make Cancer Care Heart-Safe
For all the excitement about curing cancer or the disease going into remission, the relief for some patients can often be short-lived if the treatment leaves them with other potentially long-term health repercussions. Cardiovascular...
